Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) and Vera Therapeutics (NASDAQ:VERA – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.
Risk & Volatility
Lisata Therapeutics has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.
Valuation & Earnings
This table compares Lisata Therapeutics and Vera Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lisata Therapeutics | $170,000.00 | 266.65 | -$16.59 million | ($1.91) | -2.63 |
| Vera Therapeutics | N/A | N/A | -$299.61 million | ($4.66) | -8.34 |
Lisata Therapeutics has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and target prices for Lisata Therapeutics and Vera Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lisata Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| Vera Therapeutics | 1 | 1 | 10 | 0 | 2.75 |
Lisata Therapeutics presently has a consensus price target of $15.00, indicating a potential upside of 198.80%. Vera Therapeutics has a consensus price target of $81.45, indicating a potential upside of 109.61%. Given Lisata Therapeutics’ higher possible upside, equities research analysts plainly believe Lisata Therapeutics is more favorable than Vera Therapeutics.
Profitability
This table compares Lisata Therapeutics and Vera Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lisata Therapeutics | N/A | -85.50% | -70.85% |
| Vera Therapeutics | N/A | -59.72% | -49.10% |
Institutional and Insider Ownership
8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 9.6% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 16.3% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
About Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
About Vera Therapeutics
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
